Skip to main content
S&P 5007,619.38+1.31%DOW52,486.49+0.49%NASDAQ25,466.19+1.60%BTC$73,239.00-0.96%ETH$2,038.35-0.85%GOLD$3,954.50-1.15%OIL$85.81-0.83%
Smart Investors Daily
SID Premium
IM

NASDAQ · IMRX

Immuneering Corporation

Healthcare · Biotechnology

$3.79

Down-$0.06 (-1.56%)

Updated Nov 12, 2026, 11:19 AM

SID Score

3.0/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
224.71M
P/E ratio
-3.59
Dividend yield
0.00%
52-week range
$3.35 – $6.89
Volume
455.93K
Avg. volume
1.88M

Price performance · IMRX

IMRX price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 11, 2026

IMRX closed at $3.79 after 21 trading sessions, up 10.82% for the selected period.

Last close
$3.79
Period change
+10.82%
Period low
$3.37
Period high
$4.02
Daily close
View OHLC price history
IMRX OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 11, 2026$3.89$3.95$3.79$3.79455.93K
Nov 10, 2026$3.66$3.895$3.64$3.85769.41K
Nov 9, 2026$3.69$3.725$3.53$3.65849.14K
Nov 6, 2026$3.41$3.70$3.3683$3.68681.55K
Nov 5, 2026$3.74$3.74$3.35$3.37764.4K
Nov 4, 2026$3.74$3.87$3.70$3.76730.6K
Nov 3, 2026$3.52$3.76$3.52$3.68877.87K
Nov 2, 2026$3.76$3.94$3.445$3.49799.89K
Oct 30, 2026$4.01$4.07$3.72$3.7451.14M
Oct 29, 2026$3.99$4.10$3.87$4.02777.03K
Oct 28, 2026$3.80$4.155$3.79$3.991.44M
Oct 27, 2026$3.72$3.888$3.70$3.83700.08K
Oct 26, 2026$3.73$3.78$3.65$3.71579.8K
Oct 23, 2026$3.78$3.78$3.585$3.73726.54K
Oct 22, 2026$3.72$3.835$3.70$3.81527.13K
Oct 21, 2026$3.73$3.80$3.6801$3.74481.88K
Oct 20, 2026$3.70$3.841$3.67$3.73926.84K
Oct 19, 2026$3.61$3.67$3.5601$3.66427.11K
Oct 16, 2026$3.65$3.68$3.575$3.59747.89K
Oct 15, 2026$3.42$3.71$3.38$3.64934.29K
Oct 14, 2026$3.51$3.598$3.41$3.42805.72K

Latest IMRX news

The latest Smart Investors Daily articles mentioning IMRX.

Stock researchCompany · Overview

IMRX research

Overview

Company profile and research snapshot.

Company profile

Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$21.00
Implied upside
—
Analysts
—
IMRX recent ratings
DateFirmRatingTarget
Aug 6, 2026HC Wainwright & Co.Buy—
Jul 20, 2026NeedhamBuy—
Jul 8, 2026Cantor FitzgeraldOverweight—
May 19, 2026Chardan CapitalBuy—
Mar 9, 2026NeedhamBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 4, 2026

Immuneering to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference

NEW YORK, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that management will participate in a fireside chat at the Guggenheim 3rd Annual Healthcare Innovation in Boston on Monday, November 9, 2026, at 11:00 am ET. The fireside chat will be webcast live and archived in the Investor Relations section of Immuneering’s website at Events & Presentations

Yahoo · Nov 4, 2026

Immuneering to Highlight Atebimetinib’s Broad Potential for Combinations in Pancreatic and Anaplastic Thyroid Cancers at the 2026 EORTC-NCI-AACR Symposium

- Atebimetinib in combination with chemotherapy has shown excellent results in Phase 2 clinical trials, including 17.3 months median overall survival in first-line pancreatic cancer patients treated with atebimetinib + mGnP, as presented in June at ASCO - - Poster spotlight session will highlight broad set of additional opportunities to combine atebimetinib with agents targeting multiple oncogenic pathways in pancreatic cancer - - New preclinical data supports atebimetinib’s use in a wide range

Yahoo · Oct 29, 2026

Immuneering Reports Third Quarter 2026 Financial Results and Provides Business Updates

- Phase 2 pancreatic cancer follow-up extended as patients on atebimetinib combinations live longer than projected - - Updated Phase 2 atebimetinib + mGnP pancreatic cancer data (N=55) expected in the first half of 2027 - - Phase 3 MAPKeeper 301 enrollment ahead of schedule; enrollment target expanding from 510 to 570 patients; potential to accelerate current mid-2028 topline data guidance - NEW YORK, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical

Yahoo · Oct 26, 2026

Immuneering Presents Design and Methodology of Ongoing Phase 3 MAPKeeper 301 Trial at ESMO Congress 2026

- Ongoing Pivotal Phase 3 trial evaluating atebimetinib in combination with modified gemcitabine/nab-paclitaxel versus standard-of-care chemotherapy in first-line metastatic pancreatic cancer - -MAPKeeper 301 builds on encouraging Phase 2a results presented at ASCO 2026 including median overall survival (OS) of 17.3 months - - Global, randomized Phase 3 trial ongoing, with overall survival as the primary endpoint - NEW YORK, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By